MA43684A - Liraglutide utilisé dans le traitement de maladies rénales - Google Patents
Liraglutide utilisé dans le traitement de maladies rénalesInfo
- Publication number
- MA43684A MA43684A MA043684A MA43684A MA43684A MA 43684 A MA43684 A MA 43684A MA 043684 A MA043684 A MA 043684A MA 43684 A MA43684 A MA 43684A MA 43684 A MA43684 A MA 43684A
- Authority
- MA
- Morocco
- Prior art keywords
- liraglutide
- treatment
- kidney diseases
- kidney
- diseases
- Prior art date
Links
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 title 1
- 108010019598 Liraglutide Proteins 0.000 title 1
- 208000017169 kidney disease Diseases 0.000 title 1
- 229960002701 liraglutide Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16158738 | 2016-03-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43684A true MA43684A (fr) | 2018-11-28 |
Family
ID=55484878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043684A MA43684A (fr) | 2016-03-04 | 2017-03-03 | Liraglutide utilisé dans le traitement de maladies rénales |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20190091295A1 (fr) |
| CN (1) | CN108883158A (fr) |
| MA (1) | MA43684A (fr) |
| WO (1) | WO2017149105A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3056663C (fr) | 2019-04-05 | 2022-10-18 | Jeffrey S. RIESMEYER | Utilisation du dulaglutide pour reduire le risque d'evenement cardiovasculaire chez les patients atteints du diabete de type 2 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU227021B1 (en) | 1996-08-30 | 2010-05-28 | Novo Nordisk As | Glp-1 derivatives |
| EP1687019B1 (fr) * | 2003-11-20 | 2017-11-22 | Novo Nordisk A/S | Formulations peptidiques a base de propylene glycol optimales pour la production et l'utilisation dans des dispositifs d'injection |
-
2017
- 2017-03-03 CN CN201780015191.0A patent/CN108883158A/zh not_active Withdrawn
- 2017-03-03 WO PCT/EP2017/054977 patent/WO2017149105A1/fr not_active Ceased
- 2017-03-03 MA MA043684A patent/MA43684A/fr unknown
- 2017-03-03 US US16/081,461 patent/US20190091295A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017149105A1 (fr) | 2017-09-08 |
| CN108883158A (zh) | 2018-11-23 |
| US20190091295A1 (en) | 2019-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3448263A4 (fr) | Traitement électrothérapeutique | |
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| MA45192A (fr) | Traitement d'association | |
| EP3448875A4 (fr) | Compositions pour le traitement de maladies | |
| EP3448987A4 (fr) | Compositions pour le traitement de maladies | |
| EP3359171C0 (fr) | Utilisation d'akkermansia muciniphila pour traiter des états inflammatoires | |
| EP3370703A4 (fr) | Combinaison de gemcabène pour le traitement de maladies cardiovasculaires | |
| EP3504187A4 (fr) | Utilisation de la pridopidine pour le traitement du déclin fonctionnel | |
| EP3409744A4 (fr) | Agent de traitement de surface | |
| MA46788A (fr) | Traitement de la fibrose | |
| PL3503890T3 (pl) | Stosowanie pridopidyny w leczeniu dystonii | |
| EP3431566A4 (fr) | Agent de traitement de surface | |
| MA44762A (fr) | Sémaglutide utilisé dans le traitement de maladies cardiovasculaires | |
| EP3375108A4 (fr) | Traitement dewlan | |
| MA53568A (fr) | Médicaments pour le traitement de maladies ophtalmiques | |
| MA42930A (fr) | Traitement de maladies neurodégénératives | |
| EP3316887A4 (fr) | Inhibiteurs de gls1 pour le traitement de maladies | |
| EP3735209A4 (fr) | Traitement de la progression de la myopie | |
| EP3386967A4 (fr) | Combinaisons pour le traitement de calculs rénaux | |
| MA45046A (fr) | Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules | |
| EP3344258A4 (fr) | Traitement de maladies auto-immunes et de maladies auto-inflammatoires | |
| EP3848022C0 (fr) | Agent thérapeutique pour utilisation dans le traitement d'infections | |
| EP3426307A4 (fr) | Utilisation de dreadd pour la modulation neuronale dans le traitement de maladies neuronales | |
| EP3309165A4 (fr) | Agent de traitement de surface | |
| EP3413898A4 (fr) | Utilisation de tréhalose pour le traitement de maladies neurologiques |